drugset / Trial / NCT04157985
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Timeline
- Start
- 2019-11-15
- Primary completion
- 2025-10-14
- Completion
- 2025-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | — | — |
| Comparator | Cemiplimab | Monoclonal antibody | — | — |
| Comparator | Ipilimumab | Monoclonal antibody | — | — |
| Comparator | Nivolumab | Monoclonal antibody | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |